Time for you to look at the European market for generics The US generic market is becoming very crowded. Prices may seem low to you, but to companies in India, China and several other countries they look very attractive indeed. Now those firms are moving into the US marketplace and are eating into your market share and margins. You will recognise names such as Cipla, Dr. Reddy’s, Ranbaxy and Wockhardt. These are just three that have already made their presence felt in the US generic market. Others are sure to follow. Remember, too, that the world’s two largest generic companies are not even American - they are the Swiss firm Sandoz and the Israeli Teva. Can you afford to wait for other foreign competitors to join these companies in eroding your market share? There is a solution - take the battle to the enemy and look at establishing yourself in Europe in the same way that Barr have done through Pliva and Mylan through its acquisition of Merck Generics in 2007. Want to know where to start? Interpharm Consultancy offers you: 路 In-depth knowledge of the European generic industry 路 Experience of establishing new generic business in Europe 路 Experience of working with US pharmaceutical companies 路 Understanding of the differences between the US and European markets (see my report entitled “US and European Prescription Generic Markets” for more information 路 Up-to-date knowledge of the latest European pharmaceutical legislation 路 Extensive contacts with the major players in the European generic industry 路 Clarification of how the European generic environment differs from the US We can be your English speaking bridge to Europe, allowing you to take advantage of the increasing levels of cross-border harmonisation. European generics are going through a major growth phase right now by contrast with the ever more crowded US market. You can take advantage of this opportunity before your competitors spot what is happening. Contact us now for more information:- |